AR112639A1 - Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 - Google Patents
Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39Info
- Publication number
- AR112639A1 AR112639A1 ARP180102152A AR112639A1 AR 112639 A1 AR112639 A1 AR 112639A1 AR P180102152 A ARP180102152 A AR P180102152A AR 112639 A1 AR112639 A1 AR 112639A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- adp
- antigen
- activity
- function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una proteína de unión al antígeno que se une específicamente a una CD39 humana (hCD39) que es capaz de realizar 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, ó 18 de las siguientes acciones: a) inhibir la unión de la CD39 a ATP; b) inhibir la conversión por la CD39 de ATP en ADP y/o ADP en AMP; c) disminuir la afinidad de la CD39 por ATP o ADP; d) inhibir o impedir la liberación de ADP o AMP desde CD39; e) impedir o inhibir la procesividad de CD39; f) inhibir la agregación de plaquetas; g) disminuir los niveles de fosfato, ADP, AMP, y/o adenosina y/o incrementar los niveles de ATP; h) incrementar la función de las células T efectoras; i) reducir el número de células T reguladoras en los tejidos o en la circulación; j) suprimir las células T reguladoras o la actividad de las células T reguladoras; k) incrementar la función de las células B; l) incrementar la función de las células presentadoras de antígenos; m) inhibir la función de CD39 en las células tumorales; n) inhibir el procesamiento de al menos uno de fosfo-antígeno de isoprenoide fosforilado, metabolito de vitamina B fosforilado y/o riboflavina fosforilada; o) reducir o prevenir la activación de células T específicas para fosfo-antígeno seleccionadas entre células MAIT y células T gd; p) inhibir la angiogénesis; q) incrementar la proliferación de células T CD4⁺ y CD8⁺ estimuladas; r) incrementar la secreción de PBMC, estimulada de INF-g, TNF-a, IL-2 y/o IL-1b. Reivindicación 3: Una composición farmacéutica que comprende una cantidad efectiva de un anticuerpo que se une a hCD39, que tiene 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, ó 16 de las siguientes características: a) bloquea o disminuye la hidrólisis de ATP en ADP y/o ADP en AMP tal como se determina mediante al menos uno de: (i) una disminución en la liberación de fosfato (Pi), (ii) un incremento en los niveles de ATP, y (iii) una disminución de los niveles de ADP, AMP y/o adenosina; b) incrementa la actividad de las células T efectoras; c) suprime la actividad de las células T reguladoras o disminuye la actividad de las células T reguladoras; d) disminuye el número de células T reguladoras en los tejidos o en la circulacion; e) incrementa la función de las células B; f) incrementa la función de las células presentadoras de antígenos; g) inhibe la función de CD39 en las células tumorales; h) bloquea o inhibe el procesamiento de al menos uno de: fosfo-antígeno de un isoprenoide fosforilado, metabolito de vitamina B fosforilado, y riboflavina fosforilada; i) disminuye o previene la activación de células T específicas para fosfo-antígeno seleccionadas entre células MAIT y células T gd; k) inhibe la angiogénesis; l) disminuye la afinidad por ATP y/o ADP; m) inhibe la liberación de ADP o AMP desde CD39; n) impide o inhibe la procesividad de CD39; o) inhibe la agregación de plaquetas; p) incrementa la proliferación de células T CD4⁺ y CD8⁺ estimuladas; r) incrementa la secreción de PBMC estimulada de INF-g, TNF-a, IL-2, y/o IL-1b. Reivindicación 14: Una molécula de anticuerpo aislada capaz de unirse a CD39 humana (hCD39), que comprende una región variable de la cadena pesada (VH) y una región variable de la cadena liviana (VL), VH y/o VL que comprende 1, 2, 3, 4, 5 ó 6 de: a) una VHCDR1 que tiene la secuencia establecida en las SEQ ID Nº 1 - 45, b) una VHCDR2 que tiene la secuencia establecida en las SEQ ID Nº 46 - 81, c) una VHCDR3 que tiene la secuencia establecida en las SEQ ID Nº 82 - 109, d) una VLCDR1 que tiene la secuencia establecida en las SEQ ID Nº 110 - 124, e) una VLCDR2 que tiene la secuencia establecida en las SEQ ID Nº 125 - 140, y f) una VLCDR3 que tiene la secuencia establecida en las SEQ ID Nº 141 - 166. Reivindicación 16: Un ácido nucleico aislado que codifica una proteína de unión al antígeno de acuerdo con la reivindicación 1, la reivindicación 14, o la reivindicación 15. Reivindicación 17: Un vector de expresión que comprende el ácido nucleico de acuerdo con la reivindicación 16. Reivindicación 18: Una célula hospedadora procariota o eucariota que comprende el vector de la reivindicación 17. Reivindicación 19: Un virus oncolítico que codifica el ácido nucleico de cualquiera de las reivindicaciones 16 ó 17. Reivindicación 24: Un método para modular la función del sistema inmunitario en un sujeto que lo necesita, que comprende el paso de poner en contacto una población de células inmunitarias del sujeto con una composición farmacéutica que comprende una cantidad efectiva de la proteína de unión al antígeno de la reivindicación 1, bajo condiciones tales que el sistema inmunitario es modulado. Reivindicación 46: Un método de cribado para un compuesto de ensayo que comprende una proteína de unión al antígeno de la reivindicación 1 capaz de inhibir una actividad de CD39, que comprende los pasos de: poner en contacto una muestra de ensayo que contiene CD39 con un compuesto de ensayo; y comparar la actividad de la muestra de ensayo con una muestra de control; mediante el cual una disminución en la actividad de CD39 en la muestra de ensayo comparada con la muestra de control identifica el compuesto como un compuesto que inhibe la actividad de CD39.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539527P | 2017-07-31 | 2017-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112639A1 true AR112639A1 (es) | 2019-11-20 |
Family
ID=65233024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102152 AR112639A1 (es) | 2017-07-31 | 2018-07-31 | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 |
Country Status (21)
Country | Link |
---|---|
US (5) | US11345757B2 (es) |
EP (1) | EP3661966A4 (es) |
JP (2) | JP7113071B2 (es) |
KR (1) | KR20200033928A (es) |
AR (1) | AR112639A1 (es) |
AU (1) | AU2018312251A1 (es) |
BR (1) | BR112020002012A8 (es) |
CA (1) | CA3071540A1 (es) |
CL (1) | CL2020000281A1 (es) |
CO (1) | CO2020001983A2 (es) |
CR (1) | CR20200101A (es) |
DO (1) | DOP2020000021A (es) |
IL (1) | IL272367A (es) |
MX (1) | MX2020001270A (es) |
MY (1) | MY202018A (es) |
PE (1) | PE20200617A1 (es) |
PH (1) | PH12020500240A1 (es) |
SG (2) | SG11202000820PA (es) |
TW (2) | TW202344516A (es) |
WO (1) | WO2019027935A1 (es) |
ZA (1) | ZA202000608B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
EP3596124A1 (en) | 2017-03-16 | 2020-01-22 | Innate Pharma | Compositions and methods for treating cancer |
AU2018312251A1 (en) | 2017-07-31 | 2020-02-20 | Trishula Therapeutics, Inc. | Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies |
KR20230020023A (ko) * | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
MX2020012107A (es) | 2018-06-18 | 2021-01-29 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
US20210047425A1 (en) * | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗cd39抗體組合物及方法 |
CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
CN114651013A (zh) * | 2019-11-05 | 2022-06-21 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
CA3174202A1 (en) * | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
JPWO2021260966A1 (es) * | 2020-06-25 | 2021-12-30 | ||
KR20230112632A (ko) * | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
JP2024505600A (ja) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | 結合剤およびそれを使用する方法 |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
TW202340243A (zh) | 2022-03-03 | 2023-10-16 | 美商阿克思生物科學有限公司 | 抗cd39抗體及其用途 |
WO2023168113A1 (en) * | 2022-03-04 | 2023-09-07 | Trishula Therapeutics, Inc. | Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer |
WO2023182530A1 (ja) * | 2022-03-25 | 2023-09-28 | ブライトパス・バイオ株式会社 | 抗cd39抗体 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024030956A2 (en) * | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0805871B2 (en) | 1995-01-18 | 2006-02-22 | Roche Diagnostics GmbH | Anti-cd30 antibodies preventing proteolytic cleavage and release of membrane-bound cd30 antigen |
AU5265296A (en) | 1995-04-10 | 1996-10-30 | Universite De Sherbrooke | Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology |
US6447771B1 (en) | 1999-03-19 | 2002-09-10 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
US6476211B1 (en) | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
US6387645B1 (en) | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
AU762392B2 (en) | 1998-07-16 | 2003-06-26 | Arca Biopharma, Inc. | Methods and materials relating to novel CD39-like polypeptides |
US6899875B1 (en) | 1999-01-29 | 2005-05-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6350447B1 (en) | 1999-01-29 | 2002-02-26 | Hyseq, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6780977B1 (en) | 1999-01-29 | 2004-08-24 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
US6335013B1 (en) | 1999-03-19 | 2002-01-01 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
EP1573027A4 (en) | 2001-12-17 | 2007-02-21 | Beth Israel Hospital | METHOD FOR REDUCING ANGIOGENESIS |
US20050037382A1 (en) | 2003-04-08 | 2005-02-17 | Robson Simon C. | Methods and compositions for treating and preventing autoimmune disorders |
WO2006111986A1 (en) | 2005-04-19 | 2006-10-26 | Fondazione Santa Lucia I.R.C.C.S. | Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof |
ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
EA201000921A1 (ru) | 2007-11-30 | 2010-12-30 | Бристол-Маерс Сквибб Компани | Конъюгаты антител против rg-1 |
DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
US9403904B2 (en) * | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
DK2654789T3 (en) | 2010-12-22 | 2018-09-03 | Orega Biotech | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF |
EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
TWI758928B (zh) | 2014-11-21 | 2022-03-21 | 美商必治妥美雅史谷比公司 | 抗cd73抗體及其用途 |
US20180140724A1 (en) | 2015-05-27 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer |
UA125062C2 (uk) * | 2015-10-01 | 2022-01-05 | Потенза Терапеутікс, Інк. | Анти-tigit антигензв'язуючі білки і способи їх застосування |
WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
JP2019509014A (ja) | 2015-11-23 | 2019-04-04 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Cd39血管アイソフォームターゲティング剤 |
WO2017157948A1 (en) | 2016-03-14 | 2017-09-21 | Innate Pharma | Anti-cd39 antibodies |
ES2912453T3 (es) | 2016-05-06 | 2022-05-26 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
MX2019007243A (es) | 2016-12-22 | 2019-09-06 | Calithera Biosciences Inc | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. |
EP3596124A1 (en) | 2017-03-16 | 2020-01-22 | Innate Pharma | Compositions and methods for treating cancer |
AU2018312251A1 (en) | 2017-07-31 | 2020-02-20 | Trishula Therapeutics, Inc. | Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies |
EP3692068B1 (en) | 2017-10-06 | 2022-12-07 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
AU2018368541A1 (en) | 2017-11-15 | 2020-03-19 | Innate Pharma | Potentiating the effect of ATP release |
KR20230020023A (ko) | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
US20210388105A1 (en) | 2019-08-27 | 2021-12-16 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-cd39 antibodies |
TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗cd39抗體組合物及方法 |
CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
-
2018
- 2018-07-30 AU AU2018312251A patent/AU2018312251A1/en active Pending
- 2018-07-30 BR BR112020002012A patent/BR112020002012A8/pt unknown
- 2018-07-30 JP JP2020506222A patent/JP7113071B2/ja active Active
- 2018-07-30 US US16/635,526 patent/US11345757B2/en active Active
- 2018-07-30 US US16/049,736 patent/US20190062448A1/en not_active Abandoned
- 2018-07-30 SG SG11202000820PA patent/SG11202000820PA/en unknown
- 2018-07-30 KR KR1020207005353A patent/KR20200033928A/ko not_active Application Discontinuation
- 2018-07-30 MX MX2020001270A patent/MX2020001270A/es unknown
- 2018-07-30 WO PCT/US2018/044449 patent/WO2019027935A1/en active Application Filing
- 2018-07-30 MY MYPI2020000520A patent/MY202018A/en unknown
- 2018-07-30 PE PE2020000166A patent/PE20200617A1/es unknown
- 2018-07-30 EP EP18841649.9A patent/EP3661966A4/en active Pending
- 2018-07-30 CR CR20200101A patent/CR20200101A/es unknown
- 2018-07-30 CA CA3071540A patent/CA3071540A1/en active Pending
- 2018-07-30 SG SG10202111869SA patent/SG10202111869SA/en unknown
- 2018-07-31 AR ARP180102152 patent/AR112639A1/es unknown
- 2018-07-31 TW TW112113090A patent/TW202344516A/zh unknown
- 2018-07-31 TW TW107126546A patent/TWI798242B/zh active
-
2020
- 2020-01-29 ZA ZA2020/00608A patent/ZA202000608B/en unknown
- 2020-01-30 IL IL272367A patent/IL272367A/en unknown
- 2020-01-31 DO DO2020000021A patent/DOP2020000021A/es unknown
- 2020-01-31 PH PH12020500240A patent/PH12020500240A1/en unknown
- 2020-01-31 CL CL2020000281A patent/CL2020000281A1/es unknown
- 2020-02-25 CO CONC2020/0001983A patent/CO2020001983A2/es unknown
-
2021
- 2021-09-07 US US17/468,366 patent/US20210403593A1/en not_active Abandoned
-
2022
- 2022-04-20 US US17/725,142 patent/US20220340680A1/en active Pending
- 2022-05-30 US US17/827,989 patent/US20220372163A1/en active Pending
- 2022-07-25 JP JP2022118008A patent/JP2022145720A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112639A1 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 | |
Bharaj et al. | Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals | |
Elzey et al. | The emerging role of platelets in adaptive immunity | |
AU2017249698B2 (en) | Ex vivo bite-activated T cells | |
AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
EP3134120B1 (en) | Compositions and methods for treating cytokine-related disorders | |
BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
JP2018534932A5 (es) | ||
Chung et al. | Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression | |
CL2023002744A1 (es) | Métodos de producción de células que expresan receptores de antígeno quiméricos | |
US20180267024A1 (en) | Composition for determination of cell-mediated immune responsiveness | |
BR112021026382A2 (pt) | Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer | |
Fuji et al. | Possible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
Dizaji Asl et al. | NK cell dysfunction is linked with disease severity in SARS‐CoV‐2 patients | |
Tran‐Van et al. | Measles virus modulates dendritic cell/T‐cell communication at the level of plexinA1/neuropilin‐1 recruitment and activity | |
AR093671A1 (es) | Anticuerpos monoclonales contra una proteina activada c (apc) | |
WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 | |
US20240115610A1 (en) | Genetically engineered diagnostic cells and antigen tests | |
Wu et al. | Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications | |
WO2013113092A1 (en) | Methods of determining cell mediated response | |
WO2022245813A2 (en) | A method for controlling viral infections through adoptive transfer of a cell product comprising an expanded and enriched population of superctivated cytokine killer cells |